Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations

British Journal of Haematology

Volumn 154, Issue 4, 2011, Pages 457-465

  Alvares, Caroline L ^a   Schenk, Tino ^a   Hulkki, Sanna ^b   Min, Toon ^b   Vijayaraghavan, Gowri ^a   Yeung, Jenny ^a,c   Gonzalez, David ^a   So, Chi W E ^a,c   Greaves, Mel ^a   Titley, Ian ^a   Bartolovic, Kerol ^d   Morgan, Gareth ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myeloid leukaemia; CD34+ cells; FMS like tyrosine kinase 3; Non cycling; Tyrosine kinase inhibitor

Indexed keywords

CD135 ANTIGEN; DOVITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER RESISTANCE; CELL EXPANSION; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; FEMALE; GENE DUPLICATION; GENE MUTATION; GENE REARRANGEMENT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNAL TANDEM DUPLICATION; LEUKEMIA CELL; MALE; MOUSE; NON CYCLING CD34+ LEUKEMIA CELL; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; STROMA CELL;

ADULT; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL CYCLE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MIDDLE AGED; MUTATION; PILOT PROJECTS; PROTEIN-TYROSINE KINASES; QUINOLONES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; YOUNG ADULT;

EID: 79960841155     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08748.x     Document Type: Article

References (29)

1. Anderson, K., Lutz, C., van Delft, F.W., Bateman, C.M., Guo, Y., Coleman, S.M., Kempski, H., Moorman, A.V., Titley, I., Swansbury, J., Kearney, L., Enver, T. & Greaves, M. (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature, 469, 356-361.
2. Breems, D.A., Blokland, E.A., Neben, S. & Ploemacher, R.E. (1994) Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia, 8, 1095-1104.
3. Clark, J.J., Cools, J., Curley, D.P., Yu, J.C., Lokker, N.A., Giese, N.A. & Gilliland, D.G. (2004) Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood, 104, 2867-2872.
4. de Figueiredo-Pontes, L.L., Pintao, M.C., Oliveira, L.C., Dalmazzo, L.F., Jacomo, R.H., Garcia, A.B., Falcao, R.P. & Rego, E.M. (2008) Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-reistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry. Part B, Clinical Cytometry, 74, 163-168.
5. Frohling, S., Scholl, C., Levine, R.L., Loriaux, M., Boggon, T.J., Bernard, O.A., Berger, R., Dohner, H., Dohner, K., Ebert, B.L., Teckie, S., Golub, T.R., Jiang, J., Schittenhelm, M.M., Lee, B.H., Griffin, J.D., Stone, R.M., Heinrich, M.C., Deininger, M.W., Druker, B.J. & Gilliland, D.G. (2007) Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell, 12, 501-513.
6. van Gosliga, D., Schepers, H., Rizo, A., van der kolk, D., Vellenga, E. & Schuringa, J.J. (2007) Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Experimental Hematology, 35, 1538-1549.
7. Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L. & Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99, 319-325.
8. Grundler, R., Thiede, C., Miething, C., Steudel, C., Peschel, C. & Duyster, J. (2003) Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood, 102, 646-651.
9. Guan, Y. & Hogge, D.E. (2000) Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia, 14, 2135-2141.
10. Guan, Y., Gerhard, B. & Hogge, D.E. (2003) Detection, isolation and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood, 101, 3142-3149.
11. Kelly, L.M., Yu, J.C., Boulton, C.L., Apatira, M., Li, J., Sullivan, C.M., Williams, I., Amaral, S.M., Curley, D.P., Duclos, N., Neuberg, D., Scarborough, R.M., Pandey, A., Hollenbach, S., Abe, K., Lokker, N.A., Gilliland, D.G. & Giese, N.A. (2002) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 1, 421-432.
12. Kindler, T., Lipka, D.B. & Fischer, T. (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood, 116, 5089-5102.
13. Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H. & Naoe, T. (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia, 12, 1333-1337.
14. Knapper, S., Mills, K.I., Gilkes, A.F., Austin, S.J., Walsh, V. & Burnett, A.K. (2006) The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signalling in both FLT3-mutated and wild-type cases. Blood, 108, 3494-3503.
15. Kottaridis, P.D., Gale, R.E., Langabeer, S.E., Frew, M.E., Bowen, D.T. & Linch, D.C. (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood, 100, 2393-2398.
16. Lopes de Menezes, D.E., Peng, J., Garrett, E.N., Louie, S.G., Lee, S.H., Wiesmann, M., Tang, Y., Shephard, L., Goldbeck, C., Oei, Y., Ye, H., Aukerman, S.L. & Heise, C. (2005) CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumour xenograft models of human acute myelogenous leukemia. Clinical Cancer Research, 11, 5281-5291.
17. Murphy, K.M., Levis, M., Hafez, M.J., Geiger, T., Cooper, L.C., Smith, B.D., Small, D. & Berg, K.D. (2003) Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis. The Journal of molecular diagnostics, 5, 96-102.
18. Nakao, M., Yokota, S., Iswai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. & Misawa, S. (1996) Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia, 10, 1911-1918.
19. O'Farrell, A.M., Abrams, T.J., Yuen, H.A., Ngai, T.J., Louie, S.G., Yee, K.W., Wong, L.M., Hong, W., Lee, L.B., Town, A., Smolich, B.D., Manning, W.C., Murray, L.J., Heinrich, M.C. & Cherrington, J.M. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 101, 3597-3605.
20. Parmar, A., Marz, S., Rushton, S., Holzwarth, C., Lind, K., Kayser, S., Dohner, K., Peschel, C., Oostendorp, R.A. & Goetze, K.S. (2011) Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first generation FLT3 tyrosine kinase inhibitors. Cancer Research, [epub ahead of print].
21. Pollard, J.A., Alonzo, T.A., Gerbing, R.B., Woods, W.G., Lange, B.J., Sweetser, D.A., Radich, J.P., Bernstein, I.D. & Meshinchi, S. (2006) FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood, 108, 2764-2769.
22. Schubert, M., Herbert, N., Taubert, I., Ran, D., Singh, R., Eckstein, V., Vitacolonna, M., Ho, A.D. & Zoller, M. (2011) Differential survival of AML subpopulations in NOD/SCID mice. Experimental Hematology, 39, 250-263.
23. Shih, L.Y., Huang, C.F., Wu, J.H., Wang, P.N., Lin, T.L., Dunn, P., Chou, M.C., Kuo, M.C. & Tang, C.C. (2004) Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clinical Cancer Research, 10, 1326-1332.
24. Stirewalt, D.L., Kopecky, K.J., Meshinchi, S., Appelbaum, F.R., Slovak, M.L., Willman, C.L. & Radich, J.P. (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood, 97, 3589-3595.
25. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
26. Tiesmeier, J., Muller-Tidow, C., Westermann, A., Czwalinna, A., Hoffman, M., Krauter, J., Heil, G., Ganser, A., Serve, H. & Verbeek, W. (2004) Evolution of FLT3-ITD and D835 activating mutations in relapsing acute myeloid leukemia and response to salvage therapy. Leukemia Research, 28, 1069-1074.
27. Weisberg, E., Boulton, C., Kelly, L.M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D.G. & Griffin, J.D. (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell, 1, 433-443.
28. Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrozek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. & Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233-7239.
29. Yee, K.W., O'Farrell, A.M., Smolich, B.D., Cherrington, J.M., McMahon, G., Wait, C.L., McGreevey, L.S., Griffith, D.J. & Heinrich, M.C. (2002) SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 100, 2941-2949.